Middle East & Africa Embolotherapy Market

The embolotherapy market in the Middle East & Africa is expected to grow from US$ 183.66 million in 2022 to US$ 261.89 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028. 

Widening Applications of Embolotherapy to Bolster Embolotherapy Market in Middle East & Africa during 2022–2028 

Embolization is performed within the artery (endovascular) through a steerable catheter inserted into the bloodstream and guided to the brain. Further, post-traumatic bleeding embolization is performed to stop bleeding caused by traumatic injuries. The method uses materials to block the affected vessel and stops blood flow. According to a Netcare hospital article, traumatic brain injury (TBI) is one of the leading causes of disability in South Africa, and 89,000 new cases of TBI are reported every year in the country. Thus, the rising adoption of embolization in various applications further increases the demand for embolization agents and supportive devices. Therefore, the growing applications of embolotherapy devices are expected to boost the growth of the embolotherapy market. Also, the increasing implementation of embolotherapy in the treatment of endovascular disease, traumatic injuries, cerebrovascular malformation, venous malformation, arteriovenous malformation, and pediatric vascular conditions is expected to offer lucrative opportunities for the market growth in the coming years. 

Market Overview 

The embolotherapy market in the Middle East & Africa is segmented into Saudi Arabia, the UAE, South Africa, and the rest of Middle East & Africa. In the current market scenario, Middle East is experiencing an increasing incidence of chronic diseases, such as strokes, neurological disorders, and cancer; rise in geriatric population; and adaption of unhealthy lifestyles. Moreover, acceptance and installations of modern technologies are projected to drive the market growth in this region. The high incidence of chronic diseases, the rise in aging population, and improvements in the treatment procedures of various chronic conditions are among the key factors propelling the market growth in Saudi Arabia. CVD is the most significant cause of premature death in Saudi Arabia. It accounts for ~37% of deaths in the country. As per a study, the prevalence rates of chronic diseases in Saudi Arabia has surged in the past few years, accounting for ~60 and ~73% of the total premature deaths in 2016 and 2020, respectively. Hypertension is the most common chronic disease, with prevalence rates of 26%. In addition, in the country, the incidence of uterine fibroids (UFs) at reproductive age is 21.2% in 2018 and poses a major burden on fertile Saudi women. Uterine fibroid embolization, a safe, effective, and minimally invasive procedure is becoming an important gynecological and interventional radiological procedure to treat UF. King Fahd Hospital – Al-Hofouf has successfully treated several benign uterine fibroids cases using uterine fibroid embolization, as per Al-Ahsa Health Affairs. This treatment uses a form of real-time x-ray to guide delivery of embolic agents to the uterus and fibroids. The agents block the arteries that provide blood to the fibroids and cause them to shrink and clear up. 

Middle East & Africa Embolotherapy Market Revenue and Forecast to 2028 (US$ Million) 

Middle East & Africa Embolotherapy Strategic Insights

Strategic insights for the Middle East & Africa Embolotherapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Embolotherapy Report Scope

Middle East & Africa Embolotherapy Regional Insights

The geographic scope of the Middle East & Africa Embolotherapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Embolotherapy Market Segmentation 

The Middle East & Africa embolotherapy market is segmented into product, disease indication, procedure, end user, and country. 
Based on procedure, the market is segmented into embolic agents and support devices. The embolic agents segment registered the largest market share in 2022. Based on disease indication, the market is categorized into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held the largest market share in 2022. Based on procedure, the Middle East & Africa embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization (TAE) segment held the largest market share in 2022. Based on end user, the Middle East & Africa embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the rest of the MEA. China dominated the market share in 2022. Abbott Laboratories; Boston Scientific Corporation; Cook Medical LLC; Johnson & Johnson; Medtronic; Acandis GmbH; Balt USA LLC; Stryker Corporation; Guerbet LLC; and Terumo Corporation are the leading companies operating in the embolotherapy market in the region.